Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does POLATUZUMAB VEDOTIN Cause Myelosuppression? 122 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 122 reports of Myelosuppression have been filed in association with POLATUZUMAB VEDOTIN (POLIVY). This represents 2.6% of all adverse event reports for POLATUZUMAB VEDOTIN.

122
Reports of Myelosuppression with POLATUZUMAB VEDOTIN
2.6%
of all POLATUZUMAB VEDOTIN reports
10
Deaths
39
Hospitalizations

How Dangerous Is Myelosuppression From POLATUZUMAB VEDOTIN?

Of the 122 reports, 10 (8.2%) resulted in death, 39 (32.0%) required hospitalization, and 15 (12.3%) were considered life-threatening.

Is Myelosuppression Listed in the Official Label?

Yes, Myelosuppression is listed as a known adverse reaction in the official FDA drug label for POLATUZUMAB VEDOTIN.

What Other Side Effects Does POLATUZUMAB VEDOTIN Cause?

Disease progression (1,131) Off label use (692) Anaemia (344) Blood lactate dehydrogenase increased (307) Drug ineffective (305) Neutropenia (303) Death (295) Covid-19 (286) Febrile neutropenia (286) Pyrexia (285)

What Other Drugs Cause Myelosuppression?

CYCLOPHOSPHAMIDE (3,603) CARBOPLATIN (2,624) TRASTUZUMAB (2,552) PACLITAXEL (2,522) TISLELIZUMAB (2,142) CYTARABINE (1,869) VENETOCLAX (1,864) CISPLATIN (1,849) BEVACIZUMAB (1,744) SODIUM (1,696)

Which POLATUZUMAB VEDOTIN Alternatives Have Lower Myelosuppression Risk?

POLATUZUMAB VEDOTIN vs POLATUZUMAB VEDOTIN-PIIQ POLATUZUMAB VEDOTIN vs POLIDOCANOL POLATUZUMAB VEDOTIN vs POLYETHYLENE GLYCOL POLATUZUMAB VEDOTIN vs POLYETHYLENE GLYCOL 3350 POLATUZUMAB VEDOTIN vs POLYETHYLENE GLYCOL 3350\POTASSIUM\SODIUM BICARBONATE\SODIUM

Related Pages

POLATUZUMAB VEDOTIN Full Profile All Myelosuppression Reports All Drugs Causing Myelosuppression POLATUZUMAB VEDOTIN Demographics